Assessment of the efficacy of RFA combined with intratumoral administration of cisplatin.

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10360
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Osaka City University
• Principal Investigator: Hamamoto Shinichi 大阪市立大学, 大学院医学研究科, 講師 (80711788)
• Research Collaborator: MURAI kazuki
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 肺腫瘍 / RFA / シスプラチン

Outline of Final Research Achievements

The purpose of this study is to evaluate the feasibility of combination therapy of RFA and intratumoral cisplatin injection to lung tumor. VX2 tumor colonized rabbit models were prepared, and RFA and intratumoral cisplatin injection was performed. Rabbits modeles were randomly assigned to 4 groups of control group (untreated group), RFA alone group, intratumoral cisplatin injection group, RFA + ciplatin injection group. Survivals were evaluated by by the Kaplan-Meier method. The median survival time of the control group, RFA alone group, intratumoral cisplatin injection group, RFA + intratumoral cisplatin injection group were (24.5 / 40.0 / 31.0 / 80.0 days), respectively. The survival rates on the 20th, 40th, 60th, and 80th days were (62.5%, 0%, 0%, 0% / 100%, 50%, 25%, 25% / 62.5%, 25%, 12.5% , 12.5% / 100%, 100%, 75%, 62.5%). The survival time of the combination therapy group was significantly longer than the other 3 groups.

Free Research Field

IVR学

Academic Significance and Societal Importance of the Research Achievements

肺腫瘍に対するRFAは広く行われているが、約1～2割の局所再発が見られ、より成績を向上させることが求められている。今回、我々は、ウサギ腫瘍モデルを使用し、RFAとシスプラチン局所投与で予後の延長が得られることを示せた。肺RFAやシスプラチンの局所投与は、現在の臨床的な技術では容易であり、また、シスプラチンは臨床でも広く使用されている薬剤である。よって、今後、肺癌患者に対する臨床応用への基礎データとなり得るといえる。